Delcath Systems Inc (NASDAQ:DCTH) — Market Cap & Net Worth
Market Cap & Net Worth: Delcath Systems Inc (DCTH)
Delcath Systems Inc (NASDAQ:DCTH) has a market capitalization of $396.31 Million ($396.31 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #13518 globally and #3264 in its home market, demonstrating a -0.84% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Delcath Systems Inc's stock price $16.44 by its total outstanding shares 34521647 (34.52 Million). Also see total assets of Delcath Systems Inc for a full breakdown of the balance sheet.
Delcath Systems Inc Market Cap History: 2015 to 2026
Delcath Systems Inc's market capitalization history from 2015 to 2026. Data shows change from $34.52 Trillion to $567.54 Million (-63.56% CAGR). Also see how efficiently does Delcath Systems Inc generate cash for how efficiently the company converts equity into cash flow.
Index Memberships
Delcath Systems Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.01% | #367 of 976 |
|
NASDAQ Composite
IXIC
|
$41.69 Trillion | 0.00% | #1316 of 3165 |
Weight: Delcath Systems Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Delcath Systems Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Delcath Systems Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Delcath Systems Inc stock quote for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
4.09x
Delcath Systems Inc's market cap is 4.09 times its annual revenue
Latest Price to Earnings (P/E) Ratio
129.14x
Delcath Systems Inc's market cap is 129.14 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $34.52 Trillion | $1.99 Million | -$17.97 Million | 17330144.07x | N/A |
| 2017 | $1.11 Trillion | $2.71 Million | -$45.12 Million | 409428.00x | N/A |
| 2018 | $6.77 Billion | $3.41 Million | -$19.22 Million | 1986.69x | N/A |
| 2019 | $733.58 Million | $1.58 Million | -$8.88 Million | 464.29x | N/A |
| 2020 | $618.63 Million | $1.65 Million | -$24.16 Million | 375.84x | N/A |
| 2021 | $267.54 Million | $3.56 Million | -$25.65 Million | 75.26x | N/A |
| 2022 | $124.28 Million | $2.72 Million | -$36.51 Million | 45.71x | N/A |
| 2023 | $143.61 Million | $2.06 Million | -$47.68 Million | 69.54x | N/A |
| 2024 | $415.64 Million | $37.20 Million | -$26.39 Million | 11.17x | N/A |
| 2025 | $348.67 Million | $85.23 Million | $2.70 Million | 4.09x | 129.14x |
Competitor Companies of DCTH by Market Capitalization
Companies near Delcath Systems Inc in the global market cap rankings as of September 18, 2026. Review Delcath Systems Inc (DCTH) tangible equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Delcath Systems Inc by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #125 globally with a market cap of $177.99 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #228 globally with a market cap of $109.30 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #229 globally with a market cap of $109.23 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #239 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #125 | Abbott Laboratories | NYSE:ABT | $177.99 Billion | $102.36 |
| #228 | Medtronic PLC | NYSE:MDT | $109.30 Billion | $92.60 |
| #229 | Stryker Corporation | NYSE:SYK | $109.23 Billion | $284.76 |
| #239 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
Delcath Systems Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Delcath Systems Inc's market cap moved from $34.52 Trillion to $ 567.54 Million, with a yearly change of -63.56%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $567.54 Million | +62.77% |
| 2025 | $348.67 Million | -16.11% |
| 2024 | $415.64 Million | +189.42% |
| 2023 | $143.61 Million | +15.56% |
| 2022 | $124.28 Million | -53.55% |
| 2021 | $267.54 Million | -56.75% |
| 2020 | $618.63 Million | -15.67% |
| 2019 | $733.58 Million | -89.16% |
| 2018 | $6.77 Billion | -99.39% |
| 2017 | $1.11 Trillion | -96.78% |
| 2016 | $34.52 Trillion | 0.00% |
| 2015 | $34.52 Trillion | -- |
End of Day Market Cap According to Different Sources
On Sep 17th, 2026 the market cap of Delcath Systems Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $396.31 Million USD |
| MoneyControl | $396.31 Million USD |
| MarketWatch | $396.31 Million USD |
| marketcap.company | $396.31 Million USD |
| Reuters | $396.31 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Delcath Systems Inc
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development… Read more